Mehta Tej I, Weissman Simcha, Fung Brian M, Tabibian James H
Department of Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, SD 57108, United States.
Department of Medicine, Hackensack University-Palisades Medical Center, North Bergen, NJ 07047, United States.
World J Hepatol. 2020 Apr 27;12(4):116-124. doi: 10.4254/wjh.v12.i4.116.
Primary sclerosing cholangitis (PSC) is a chronic, progressive, hepatobiliary disease characterized by inflammation and fibrosis of the intra- and extra-hepatic bile ducts. Its natural history is one that generally progresses towards cirrhosis, liver failure, cholangiocarcinoma, and ultimately disease-related death, with a median liver transplantation-free survival time of approximately 15-20 years. However, despite its lethal nature, PSC remains a heterogenous disease with significant variability in outcomes amongst different regions of the world. There are also many regions where the outcomes of PSC have not been studied, limiting the overall understanding of this disease worldwide. In this review, we present the geoepidemiologic variations in outcomes of PSC, with a focus on survival pre- and post-liver transplantation as well as the concurrence of inflammatory bowel disease and hepatobiliary neoplasia.
原发性硬化性胆管炎(PSC)是一种慢性、进行性肝胆疾病,其特征为肝内和肝外胆管的炎症和纤维化。其自然病程通常会发展为肝硬化、肝衰竭、胆管癌,并最终导致与疾病相关的死亡,无肝移植情况下的中位生存时间约为15至20年。然而,尽管PSC具有致命性,但它仍是一种异质性疾病,在世界不同地区的预后存在显著差异。此外,还有许多地区尚未对PSC的预后进行研究,这限制了全球对该疾病的整体认识。在本综述中,我们阐述了PSC预后的地理流行病学差异,重点关注肝移植前后的生存情况以及炎症性肠病和肝胆肿瘤的并发情况。